Evidence map›Paper›PMID 39950014›Full record

ArticleJournal of applied statistics2025

Sample size calculation for the sequential parallel comparison design with binary endpoint using exact methods.

Guogen Shan, Yahui Zhang

Abstract read
In one paragraph

Article in Journal of applied statistics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Guogen ShanDepartment of Biostatistics, University of Florida, Gainesville, FL, USA.
Yahui ZhangDepartment of Biostatistics, University of Florida, Gainesville, FL, USA.

Funding

Alzheimer's Disease: New Trial Designs for Emerging ChallengesR01AG070849 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI SHAN, GUOGEN · 2021 to 2025
$1.5M
Application of deep learning and novel survival models to predict MCI-to-AD dementia progressionR03AG083207 · NIA · UNIVERSITY OF FLORIDA · PI SHAN, GUOGEN · 2023 to 2024
$164k
NIA NIH HHS R01 AG070849NIA NIH HHS R03 AG083207
6 · The paper itself

Abstract

High placebo responses in clinical trial could reduce the treatment effect leading to the failure of a promising drug. Several strategies have been developed to minimize high placebo responses, including the sequential parallel comparison design (SPCD). For a study with binary outcome, the existing statistical methods to test the drug effectiveness always rely on the asymptotic limiting distribution. When a study's sample size is small to medium, the asymptotic approaches do not have satisfactory performance with regard to type I error rate and statistical power. For that reason, we propose utilizing exact conditional approach to calculate sample size based on the existing test statistics to order the sample space. The proposed method controls the type I error rate under the unconditional framework. We compare the proposed exact sample sizes using different test statistics and the sample size for a randomized parallel study. We would recommend using exact sample sizes for the SPCD with small- to medium sample sizes and the SPCD with extreme response rates.

Indexed as

62K0562L05Binary endpointexact approachplacebo responsesequential parallel comparison design

Identifiers

PMID39950014
PMCPMC11816656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.